Cancer Prevention Campaign for Young Adults

Recruiting at 4 trial locations

Overseen By David Buller, PhD

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Klein Buendel, Inc.

Disqualifiers: Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1000 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the Cancer Prevention Campaign for Young Adults treatment?

The survey in New Hampshire and Vermont highlights that rural areas face higher cancer mortality and challenges like smoking and financial hardship, which are linked to lower education levels. These findings suggest that targeted interventions, like the Cancer Prevention Campaign, could address these risk factors and improve cancer prevention in rural areas. ^{1 2 3 4 5}

Is the Cancer Prevention Campaign for Young Adults treatment safe for humans?

The research shows that many cancer studies focus on effectiveness, but some do look at safety. However, most studies don't have enough participants to find rare side effects, so more reporting and participation are needed to ensure safety. ^{6 7 8 9 10}

How is the Cancer Prevention Campaign for Young Adults treatment different from other cancer prevention treatments?

The Cancer Prevention Campaign for Young Adults is unique because it focuses on community-tailored education and screening interventions specifically designed for young adults in rural areas, addressing their unique knowledge gaps and healthcare access issues. This approach is different from standard treatments as it emphasizes community engagement and education rather than medical or pharmaceutical interventions. ^{3 11 12 13 14}

What is the purpose of this trial?

Young adults aged 18-26 engage in a number of behaviors that increase their risk of developing cancer later in life including sedentary lifestyles, unhealthy eating, nicotine produce us, heavy drinking of alcohol, increased UV exposure, and incomplete uptake of HPV vaccination. A multi-risk factor campaign will be developed to reduce these cancer risk behaviors and delivered to young adults over social media, a popular channel that can reach nearly all young adults. The campaign will be evaluated for effectiveness in a rigorous randomized trial with measures of moderate to vigorous physical activity, healthy eating patterns, nicotine product use, alcohol intake, sunburn prevalence, and HPV vaccination uptake.

Research Team

David Buller, PhD

Principal Investigator

Klein Buendel, Inc.

Eligibility Criteria

This trial is for young adults aged 18-26 living in rural areas of Arizona, Colorado, New Mexico, or Utah who are active on social media. They must speak and read English and consent to participate. Pregnant individuals or those with low/no social media activity cannot join.

Inclusion Criteria

Consents to participate

Accepts screening call from study staff

Resides in a county coded as RUCC 4-9 in Arizona, Colorado, New Mexico, or Utah

Exclusion Criteria

Does not give permission for engagement data to be extracted from Facebook private group

Cannot speak and read English

Does not consent to participate

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive a social media campaign designed to reduce cancer risk behaviors through private Facebook groups

24 months

Ongoing online engagement

Follow-up

Participants are monitored for changes in cancer risk behaviors and knowledge after the intervention

4 weeks

Treatment Details

Interventions

• 4 Corners Rural Health Cancer Prevention

Trial Overview The study tests a multi-risk factor campaign aimed at reducing cancer risk behaviors among young rural adults using social media. It focuses on improving physical activity, diet, reducing nicotine and alcohol use, lowering UV exposure, and increasing HPV vaccination rates.

Participant Groups

Group I: 4 Corners Rural Cancer Prevention Experimental Treatment 1 Intervention

Four separate Facebook groups, which provide information via posts within the private groups about cancer risk factors (e.g. reducing alcohol consumption, tobacco use cessation, increasing physical activity), behavioral skills to reduce them, benefits of, social support for, and ways to reduce social/financial costs of cancer prevention, and advice from health care providers to decrease barriers. Posts will seek to improve self- and response-efficacy and perceived risk, and link cancer prevention to personal goals.

Who Is Running the Clinical Trial?

Klein Buendel, Inc.

Lead Sponsor

Trials

41

Recruited

20,000+

University of New Mexico

Collaborator

Trials

393

Recruited

3,526,000+

University of Arizona

Collaborator

Trials

545

Recruited

161,000+

University of Colorado, Denver

Collaborator

Trials

1,842

Recruited

3,028,000+

University of Utah

Collaborator

Trials

1,169

Recruited

1,623,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Colorado State University

Collaborator

Trials

138

Recruited

38,200+

Findings from Research

A pharmacist-led program effectively managed adverse events in 123 patients with EGFR mutation-positive non-small cell lung cancer receiving afatinib, highlighting the importance of patient education and proactive monitoring in a community oncology setting.

Common adverse events included diarrhea (85%) and rash/skin reactions (58%), with 13% of patients discontinuing treatment due to these side effects; however, those who continued treatment often had dose reductions, indicating a strategy to maintain therapy despite adverse effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. Khrystolubova, N., Shieh, M., Patel, AJ., et al.[2020]

A new tool for clinicians in inpatient oncology units has been developed to prevent adverse events and enhance patient safety, focusing specifically on cancer patients.

The tool includes a catalog of adverse events and a risk map, which helps healthcare providers implement best practices in their daily activities to improve clinical safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improving patient safety in the inpatient setting through risk assessment and mitigation. Reche Navarro, MN.[2016]

References

1. Canada pubmed.ncbi.nlm.nih.gov

The Effects of Coaching Patients to List Questions Before Visiting Cancer Specialists: Retrospective Evaluation of Visit Preparation in a Rural, Underserved Setting. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont. [2023]

3. United States pubmed.ncbi.nlm.nih.gov

The impact of cancer coalitions on the dissemination of colorectal cancer materials to community organizations in rural Appalachia. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Clinical trial enrollment of rural patients with cancer. [2019]

5. United States pubmed.ncbi.nlm.nih.gov

Clinical cancer trials in a rural community cancer center in Southwest Oklahoma from 2000-2009. [2013]

6. United States pubmed.ncbi.nlm.nih.gov

Patient safety problem identification and solution sharing among rural community pharmacists. [2013]

7. United States pubmed.ncbi.nlm.nih.gov

Post-Discharge Adverse Events Among Urban and Rural Patients of an Urban Community Hospital: A Prospective Cohort Study. [2019]

8. Switzerland pubmed.ncbi.nlm.nih.gov

Characteristics of Phase IV Clinical Trials in Oncology: An Analysis Using the ClinicalTrials.gov Registry Data. [2023]

9. England pubmed.ncbi.nlm.nih.gov

Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. [2020]

10. United States pubmed.ncbi.nlm.nih.gov

Improving patient safety in the inpatient setting through risk assessment and mitigation. [2016]

11. United States pubmed.ncbi.nlm.nih.gov

The green acres effect: the need for a new colorectal cancer screening campaign tailored to rural audiences. [2008]

12. United States pubmed.ncbi.nlm.nih.gov

Facilitators of Multisector Collaboration for Delivering Cancer Control Interventions in Rural Communities: A Descriptive Qualitative Study. [2022]

13. England pubmed.ncbi.nlm.nih.gov

Reaching Rural Residents to Identify Colorectal Cancer Education and Intervention Targets. [2023]

14. United States pubmed.ncbi.nlm.nih.gov

Analysis of Cancer Knowledge, Attitudes, and Practices in Adolescents and Young Adults in Two Texas Rural Communities. [2023]